Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients - Summary - MDSpire
Advertisement
Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients
Jacqueline Garcia, MD, of Dana-Farber Cancer Institute presented at #ASH24 data suggesting oral maintenance therapy with venetoclax and decitabine/cedazuridine after HCT is safe, feasible, and may reduce relapse rates in high-risk AML/MDS patients.
To evaluate the safety and feasibility of oral maintenance therapy with venetoclax and decitabine/cedazuridine after hematopoietic cell transplantation (HCT) in high-risk AML/MDS patients.
Key Findings:
87% of patients were able to initiate planned maintenance therapy.
Median cycles delivered were 8, aligning with the intended treatment plan.
No grade 3 or 4 non-hematologic toxicities were observed.
One-year overall survival was 81%, and one-year progression-free survival was 73%.
Cumulative incidence of relapse at one year was 27%.
Interpretation:
The study suggests that oral maintenance therapy is a safe and feasible option for high-risk AML/MDS patients post-transplant, potentially reducing relapse rates.
Limitations:
Small sample size of 30 patients.
Short follow-up duration of 22 months.
Conclusion:
The findings support the use of an all-oral maintenance strategy for high-risk AML/MDS patients undergoing reduced intensity transplantation, showing promising early efficacy and tolerability.
